Broadened eligibility criteria for SOLACE2 as accrual nears 75% milestone

SOLACE2 is a phase II national clinical trial investigating whether immunological priming could improve the subsequent response to immunotherapy in women with the most common type of ovarian cancer (high-grade serous) at the first sign of [...]